127 studies found for:    "Clear cell renal cell carcinoma"
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Drug: Everolimus
2 Unknown  Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Conditions: Clear Cell Renal Cell Carcinoma;   Metastasis
Intervention: Drug: Sunitinib
3 Terminated Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Hereditary Clear Cell Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: sorafenib tosylate;   Procedure: diffusion-weighted magnetic resonance imaging
4 Completed Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: tandutinib;   Other: laboratory biomarker analysis
5 Recruiting Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Terminated
Has Results
Vandetanib to Treat Advanced Kidney Cancer
Condition: Advanced Clear Cell Renal Carcinoma
Intervention: Drug: vandetanib
7 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
8 Recruiting AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
9 Completed
Has Results
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Imatinib
10 Recruiting Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Lu-177-DOTA-girentuximab
11 Recruiting Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Condition: Kidney Cancer
Interventions: Drug: Pazopanib;   Drug: Temsirolimus;   Behavioral: Quality of Life Assessment;   Drug: Benadryl
12 Completed
Has Results
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: 124-Iodine-cG250 (124I-cG250);   Procedure: CT
13 Recruiting Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
14 Recruiting Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: bevacizumab;   Biological: anti-endoglin monoclonal antibody TRC105;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Active, not recruiting Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
16 Active, not recruiting Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: vorinostat;   Drug: bevacizumab
17 Completed Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
18 Completed Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Procedure: computed tomography
19 Terminated
Has Results
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Procedure: therapeutic conventional surgery;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
20 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years